Identity and sequence
Confirms material matches the intended payload.
Technical discussionProgram-specific method and result not presented; define and verify per program.
Driessen-Kerr · Driessen Group · NM-mRNADesign · Process · Scale
FROM ARCHITECTURE
TO TECHNOLOGY TRANSFER.
NM-mRNA / in one sentence
An approach to connecting decisions on payload, composition, process, quality and transfer in the design of each mRNA product system.
NM-mRNA is Driessen-Kerr's approach to integrating payload, composition, process, stability and transfer in mRNA product systems. An architecture designed for consistent technical decisions and broad-reach applications.
See the five architecture decisions ↓Technology CoreApplied science · mRNA
Engineering PriorityDelivery · Process · Scale
Cumulative AdvantageLearning · Transfer · Memory
Illustrative SEM: human B lymphocyte. Not a Driessen-Kerr product or experimental result. NIAID · CC BY 2.0 · desaturated and toned.
— 01The Real Bottleneck
An unmet need is not, by itself, a program.
A health solution needs more than a molecular hypothesis: composition, production, control, transfer and evaluation criteria must work together.
Driessen-Kerr treats composition, process and evidence as connected decisions. The aim is to reduce technical risk before it becomes a scale, cost or transfer risk.
01
COMPOSITION
The excipient system must be compatible with the payload, method and product route.
02
PROCESS
A promising formulation advances only if it can be reproduced and transferred without losing critical attributes.
03
SCALE
Capacity, cost, control and release must be considered before the development decision.
— 02Applied Science Discipline
The differentiator is not saying mRNA. It is making it operable.
Driessen-Kerr's applied-science approach organizes decisions between molecular hypothesis and product: each hypothesis should inform critical attributes, composition, process, stability, release and the next assay.
The method connects science and product-engineering decisions, organizes learning across programs and provides a common basis for technical discussions with partners.
01 //
SCIENCE → PRODUCT
Translate biology into product attributes, testable formulations and analytical methods.
02 //
CLOSED LOOP
Use every result to update the next decision, not simply archive data.
03 //
TRANSFER BY DESIGN
Design stability, release and scale before industrial transfer.
04 //
PROGRAM MEMORY
Accumulate applied learning across mRNA, delivery, process and evidence between programs.
— 03mRNA Product Architecture
From sequence to batch — without skipping steps.
The platform organizes decisions that usually arrive too late: critical quality attributes, practical composition, process design, stability and release criteria. Each layer can be audited without turning a hypothesis into a result.
Five connected decisions / scope defined per application
01 //
Payload
which sequence and critical attribute define the product
02 //
Composition
which excipient system is practical
03 //
Process
how to produce with repeatability and transfer
04 //
Stability
how to preserve integrity until release
05 //
Evidence
which data allows disciplined advancement
This sequence guides technical questions; it does not certify that studies, production or transfer have been completed. The qualification route and any potential transfer are defined with each partner.
01
Operational
current processes and surfaces
02
Product systems
program architecture
03
Translational science
methods and criteria
04
Partnerships
technical dialogue
— 03ADefinition and Boundaries
What Driessen-Kerr calls NM-mRNA.
NM-mRNA names Driessen-Kerr's approach to mRNA product-system architecture. Payload, composition, process, characterization, stability and transfer are addressed together, with technical scope defined for each application.
Performance, quality and application parameters are discussed with partners according to the product, indication and relevant technical requirements.
— 03BCritical Quality Attributes
Attributes guiding each application.
Identity, integrity, composition, stability and function guide technical characterization. Methods and criteria depend on the payload, formulation and application under discussion.
| Attribute | Why it matters | Technical discussion |
|---|---|---|
| Identity and sequence | Confirms material matches the intended payload. | Program-specific method and result not presented; define and verify per program. |
| Payload selection | Connects the biological question to the intended product and attributes to assess. | Payload and program rationale not specified on this page; program-dependent decision. |
| Composition and compatibility | Can affect association, integrity, stability and functional performance. | Formulation and payload compatibility not demonstrated here; assess per program. |
| Process and in-process controls | Links operations and parameters to material characteristics and repeatability. | Parameters, controls and campaign data not presented; define and qualify. |
| Integrity | Assesses RNA degradation and preservation through processing and storage. | Formulation data not presented; method and limits to qualify. |
| Purity and impurities | Characterizes relevant related species and process impurities. | Panel and results not presented; define for the process. |
| Concentration | Informs content per volume and consistency across samples or batches. | Quantitative result not presented; establish method and criterion. |
| Size and distribution | Helps characterize the particle population when relevant to the formulation. | Characterization not presented; applicability and method to define. |
| Encapsulation / association | Distinguishes matrix-associated from free material, as relevant to the architecture. | Efficiency not demonstrated on this page; method and criterion per formulation. |
| Potency / function | Assesses measurable biological activity in an appropriate assay. | Assay and functional data not presented; define model and endpoint. |
| Microbial controls and endotoxins | Supports assessment of microbiological quality and product safety. | Limits and batch results not presented; requirements depend on product route. |
| Stability | Determines changes over time under defined conditions. | Profile and shelf life not established here; product-specific study needed. |
| Packaging and storage | Conditions can affect protection, handling and shelf life. | Configuration and conditions are not specified as qualified; define and assess per product. |
Payload selection
Connects the biological question to the intended product and attributes to assess.
Technical discussionPayload and program rationale not specified on this page; program-dependent decision.
Composition and compatibility
Can affect association, integrity, stability and functional performance.
Technical discussionFormulation and payload compatibility not demonstrated here; assess per program.
Process and in-process controls
Links operations and parameters to material characteristics and repeatability.
Technical discussionParameters, controls and campaign data not presented; define and qualify.
Integrity
Assesses RNA degradation and preservation through processing and storage.
Technical discussionFormulation data not presented; method and limits to qualify.
Purity and impurities
Characterizes relevant related species and process impurities.
Technical discussionPanel and results not presented; define for the process.
Concentration
Informs content per volume and consistency across samples or batches.
Technical discussionQuantitative result not presented; establish method and criterion.
Size and distribution
Helps characterize the particle population when relevant to the formulation.
Technical discussionCharacterization not presented; applicability and method to define.
Encapsulation / association
Distinguishes matrix-associated from free material, as relevant to the architecture.
Technical discussionEfficiency not demonstrated on this page; method and criterion per formulation.
Potency / function
Assesses measurable biological activity in an appropriate assay.
Technical discussionAssay and functional data not presented; define model and endpoint.
Microbial controls and endotoxins
Supports assessment of microbiological quality and product safety.
Technical discussionLimits and batch results not presented; requirements depend on product route.
Stability
Determines changes over time under defined conditions.
Technical discussionProfile and shelf life not established here; product-specific study needed.
Packaging and storage
Conditions can affect protection, handling and shelf life.
Technical discussionConfiguration and conditions are not specified as qualified; define and assess per product.
— 03CScale by Design
Scale begins in product design.
The approach considers process, materials, yield, controls and transfer from the outset. Capacity and performance are assessed for each product with qualified facilities, partners and production runs.
Access goals guide the design; cost per dose is determined by each product's yield, inputs, capacity, controls, packaging and logistics.
01 //
Materials and unit operations
Define input specifications, unit operations and process dependencies.
02 //
Parameters and controls
Identify critical parameters and in-process controls linked to target attributes.
03 //
Methods and release
Develop fit-for-purpose methods, acceptance criteria and a release strategy.
04 //
Comparability and scale-up
Assess effects of scale, equipment, site and batch changes using comparable data.
— 03DTransfer Stages
Transfer tailored to each application.
A transfer discussion starts with the application, quality requirements and relevant evidence. Access to technical materials and confidentiality terms are aligned with scope and availability.
01 //
Define the program
Indication, target product profile, intended payload, scope and decision criteria.
02 //
Agree on technical exchange
Where needed, establish confidentiality and identify available, authorized materials for sharing.
03 //
Assess partner and site
Review capacity, equipment, controls and requirements relevant to the process.
04 //
Adapt the process
Translate requirements into instructions, parameters and controls suitable for the selected site.
05 //
Produce an engineering batch
Plan execution and document deviations, sampling and process results.
06 //
Characterize and compare
Assess defined attributes and comparability to reference material, where available.
07 //
Make an advancement decision
Use results to decide whether to repeat, adjust, expand studies or stop the route.
— 04Core Program · mRNA
mRNA Product Systems
The NM-mRNA approach connects payload, composition, stability, analytical methods and transfer within one product architecture. Technical scope and evaluation criteria are defined with each partner.
Access by design
Expanding access guides decisions about process, transfer and cost per dose. Specific capacity and conditions are addressed in institutional conversations for each program.
Product and Process Architecture
1. Product architecture & critical attributes[INTEGRATION]
2. Composition & process parameters[BY APPLICATION]
3. Process design & scale-up[DESIGN FOR SCALE]
4. Stability, release & analytical methods[PRODUCT CONTROLS]
5. Program functional evaluation[BY APPLICATION]
6. Clinical & regulatory strategy[BY JURISDICTION]
— 05Product Layers
mRNA architecture. Connected decisions.
The nutrigenomic program and mRNA product systems address different applications. Each program organizes its own composition, biological context and technical criteria, without confusing EPITIDE™ with an mRNA-containing product.
VAL-01 //
Nutrigenômica
Composition, biomarkers and endpoints guide the discussion of nutrigenomic applications.
Per program
VAL-02 //
EPINUTRITION
A precision nutrition surface used to learn about composition, adherence, ingredient documentation and use context — without taking the place of mRNA technology.
Operational
VAL-03 //
Translational Evidence
Integrates product data, functional assays, biomarkers and endpoints into program-specific decisions.
BY PROGRAM
— 06Program Framework
An integrated strategy for each application.
From product design to regulatory strategy, the approach connects the technical considerations a partner needs to discuss for its application. Data sharing and diligence scope are handled individually.
01INTEGRATION
Product architecture
Connect application, payload, composition and critical attributes.
02METHODS AND DATA TO DEFINE
Analytical characterization
Select methods and criteria for identity, integrity, purity, concentration and applicable attributes.
03PROGRAM-DEPENDENT
Functional proof
Define an assay, model and endpoint to test the intended product function.
04PROGRAM-DEPENDENT
In vivo evaluation
Where justified, plan model, design, comparators and criteria before execution.
05BY PRODUCT
Stability
Relate conditions, packaging and criteria to the product.
06BY PARTNERSHIP
Transfer and comparability
Align process criteria, comparability and partners.
07BY APPLICATION
Clinical strategy
Consider the product, indication, population and relevant evidence.
08BY JURISDICTION
Regulatory pathway
Map requirements relevant to the jurisdiction and intended use.
— 07Diligence Map
Diligence items
These items guide application-specific diligence; shareable documents depend on scope and available materials.
- —Critical quality attributes, integrity and analytical methods
- —Composition, suppliers and rationale for the excipient system
- —Process parameters, yield, reproducibility and scale route
- —Stability, release, packaging and jurisdiction-specific regulatory strategy
Critical questions
- ?Which product profile defines the first mRNA use case?
- ?Which composition is compatible with production, cost and release method?
- ?Which process can be transferred without losing critical attributes?
- ?Which partner has the technical and industrial capacity for the next stage?
Potential impact — contingent on validation
FOR RESEARCH
More discipline for connecting product architecture, assay and development decision.
FOR INDUSTRY
An mRNA thesis that considers composition, process and transfer before committing scale capital.
FOR CAPITAL
Diligence criteria that make technical risk, industrial readiness and the next milestone more legible.
— 08Partnership Paths
Industry · Capacity · Long-Term CapitalTransfer
Transfer
with rigor.
Research, development, manufacturing and strategic-capital partners can explore NM-mRNA applications in a technical conversation. Scope, shareable materials and collaboration criteria are defined case by case. This pathway is separate from EPITIDE™.
01. Product Co-Development
Composition, Process and Evidence
Potential collaboration to define critical attributes, composition, analytical methods and process requirements for a product, indication and jurisdiction.
02. Capacity & Transfer
From Bench to Industrial Route
Any potential transfer would require an assessed partner and site, process adaptation, an engineering batch, comparability, quality controls and applicable regulatory requirements.